Jianqing Lin

560 citations
13 papers · 333 indexed · h-index 6

Jianqing Lin

12 papers receiving 330 citations

Peers

Jianqing Lin
Comparison fields: 5 of 65
  • Cancer Research 150
  • Cell Biology 75
  • Molecular Biology 175
  • Immunology and Allergy 15
  • Biochemistry 17
Replace Rita Lombardi with:
Rita Lombardi Italy
Ying Song China
David Schlütermann Germany
Kristy Kwan‐Shuen Chan Hong Kong
Akira Kugimiya Japan
Shari L. Caplan United States
Shuzhen Chen China
Bu‐Nam Jeon South Korea
Octavio Galindo‐Hernández Mexico
Jianqing Lin relative to Rita Lombardi Italy Rita Lombardi's profile →
Citations per field
00.5×3.1×
Rita Lombardi · 1×
Citations per year

Countries citing papers authored by Jianqing Lin

Since Specialization
Citations

This map shows the geographic impact of Jianqing Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianqing Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianqing Lin more than expected).

Fields of papers citing papers by Jianqing Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianqing Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianqing Lin. The network helps show where Jianqing Lin may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jianqing Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jianqing Lin Line = papers co-authored together Jianqing Lin links everyone, so they are left out of the graph.

All Works

13 of 13 papers shown
#Work
1 20251
2 20241
3 20242
4 20236
5 20234
6 20223
7 20215
8 20209
9 20206
10 201910
11 201810
12
[Role of 6% hydroxyethylstarch 130/0.4 and furosemide in the treatment of acute pancreatitis].
20102
13
Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells.
2002274

About Jianqing Lin

Jianqing Lin is a scholar working on Infectious Diseases, Molecular Medicine and Endocrinology, having authored 13 papers that have together received 333 indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (2 papers), Computational Drug Discovery Methods (2 papers), Biochemical and Molecular Research (2 papers), Peptidase Inhibition and Analysis (2 papers), Bacterial Genetics and Biotechnology (2 papers), HIV/AIDS drug development and treatment (2 papers), Muscle and Compartmental Disorders (1 paper) and Tuberculosis Research and Epidemiology (1 paper). The work is most often cited by research in Cancer Research (150 citations), Cell Biology (75 citations) and Molecular Biology (175 citations). Jianqing Lin has collaborated with scholars based in Singapore, China and Australia. Frequent co-authors include Liyan Zhuang, Michael R. Freeman, Michael L. Lu, Keith R. Solomon, Julien Lescar, Abbas El Sahili, Boon Chong Goh, Siu Kwan Sze, Nicolai Müller and Martin Savko. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026